[ATRA] Atara Biotherapeutics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization: 622.51 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 15.65 Change: 1.15 (7.93%)
Ext. hours: Change: 0 (0%)

chart ATRA

Refresh chart

Description: Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of muscle wasting conditions and oncology. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. The company is also developing STM 434, a targeted therapy for ovarian cancer and other solid tumors; and a pipeline of product candidates that are in preclinical development. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in Brisbane, California.

Fundamental Ratios
Shares Outstanding28.74 M EPS-3.05 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-4.18
P/E To EPS Growth P/S P/BV3.75 Price/Cash Per Share3.73
Price/Free Cash Flow-37.33 ROA-17.74% ROE-18.13% ROI
Current Ratio48.29 Quick Ratio Long Term Debt/Equity Debt Ratio0.02
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities69.49 M Cash From Investing Activities-13.43 M Cash From Operating Activities-6.62 M Gross Profit
Net Profit-9.16 M Operating Profit-9.31 M Total Assets169.82 M Total Current Assets169.69 M
Total Current Liabilities3.51 M Total Debt Total Liabilities3.72 M Total Revenue
Technical Data
High 52 week46.05 Low 52 week23.99 Last close23.99 Last change-0.74%
RSI24.66 Average true range2.16 Beta1.91 Volume116.19 K
Simple moving average 20 days-21.91% Simple moving average 50 days-31.48% Simple moving average 200 days-35.01%
Performance Data
Performance Week-7.73% Performance Month-26.37% Performance Quart-40.69% Performance Half-30.98%
Performance Year-45.66% Performance Year-to-date-30.94% Volatility daily5.98% Volatility weekly13.37%
Volatility monthly27.4% Volatility yearly94.93% Relative Volume166.51% Average Volume589.17 K
New High New Low

News

2020-06-05 16:15:00 | Atara Biotherapeutics Announces its 2020 Annual Meeting of Stockholders Will Be Held on June 16, 2020 in Virtual Format

2020-06-04 16:01:00 | Atara Biotherapeutics to Participate at Two Upcoming Conferences

2020-05-27 01:16:00 | Atara Biotherapeutics Announces Pricing of $175.5 Million Public Offering

2020-05-26 16:05:00 | Atara Biotherapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

2020-05-26 07:00:00 | Atara Biotherapeutics Presents Data Demonstrating Safety & Sustained Disability Improvement at 12 Months with ATA188 in Patients with Progressive Multiple Sclerosis in Late-Breaking e-Poster at the 2020 European Academy of Neurology Virtual Congress

2020-05-19 08:30:00 | Atara Biotherapeutics to Present Late-Breaking ATA188 Data in Progressive Multiple Sclerosis at 2020 European Academy of Neurology EAN Virtual Congress

2020-05-18 16:30:00 | Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635C4

2020-05-18 12:00:04 | Atara Biotherapeutics ATRA Moves to Strong Buy: Rationale Behind the Upgrade

2020-05-15 09:38:00 | Atara Biotherapeutics Announces Presentation of Late-Breaking Preclinical Data on ATA2271, a Next-Generation Autologous CAR T Immunotherapy Targeting Mesothelin, at the American Association for Cancer Research AACR Virtual Annual Meeting II 2020

2020-05-14 16:05:00 | Atara Biotherapeutics Names Cell Therapy & Oncology Leader Jakob Dupont, M.D. as Global Head of Research & Development

2020-05-13 09:21:01 | Why Atara Biotherapeutics ATRA Stock Might be a Great Pick

2020-05-11 16:01:00 | Atara Biotherapeutics Announces Appointment of Cell & Gene Therapy Expert Maria Grazia Roncarolo, MD to Board of Directors

2020-05-11 11:25:03 | Will Atara Biotherapeutics Continue to Surge Higher?

2020-05-07 14:00:33 | Atara Biotherapeutics Inc ATRA Q1 2020 Earnings Call Transcript

2020-05-07 07:29:02 | Edited Transcript of ATRA earnings conference call or presentation 6-May-20 8:30pm GMT

2020-05-06 16:01:00 | Atara Biotherapeutics Announces First Quarter 2020 Financial Results and Operational Progress

2020-04-30 16:01:00 | Atara Biotherapeutics to Announce First Quarter 2020 Financial Results on Wednesday, May 6, 2020

2020-04-30 08:30:00 | Atara Biotherapeutics Appoints Biotech and Finance Industry Veteran Ron Renaud as Non-Executive Chair of the Board of Directors

2020-04-22 20:30:00 | Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635C4

2020-04-14 16:41:53 | Seth Klarman Dials Down Akebia Therapeutics Stake

2020-04-02 08:33:00 | Company Profile for Atara Biotherapeutics, Inc.

2020-04-02 08:30:00 | Atara Biotherapeutics Provides Update in Context of COVID-19 Pandemic

2020-03-26 10:19:09 | Is Atara Biotherapeutics NASDAQ:ATRA In A Good Position To Deliver On Growth Plans?

2020-02-28 07:04:32 | Edited Transcript of ATRA earnings conference call or presentation 27-Feb-20 1:00pm GMT

2020-02-27 07:35:07 | The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy

2020-02-27 07:30:10 | Atara Biotherapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Recent Clinical, Operational and Strategic Progress

2020-02-27 06:00:00 | Atara Biotherapeutics, Inc. to Host Earnings Call

2020-02-21 16:00:10 | Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635C4

2020-02-20 16:00:10 | Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences

2020-02-19 16:00:10 | Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 27, 2020

2020-02-05 08:30:10 | Atara Biotherapeutics Names Kristin Yarema as Chief Commercial Officer

2020-01-12 14:00:10 | Atara Biotherapeutics to Present 2020 Key Milestones and Progress in Bringing Off-The-Shelf, Allogeneic T-Cell Immunotherapies to Patients in Need at the 38th Annual J.P. Morgan Healthcare Conference

2019-12-24 10:10:03 | Trade Deal Optimism Fuels Santa Rally: ETFs & Stocks to Bet On

2019-12-18 07:59:12 | 5 Beaten-Down Biotech Stocks Set to Rebound in 2020

2019-12-11 23:04:59 | Hedge Funds Have Never Been More Bullish On Atara Biotherapeutics Inc ATRA

2019-12-10 12:22:22 | Seth Klarman Pares Paratek Pharmaceuticals Stake

2019-12-09 10:00:10 | Atara Biotherapeutics Reports Updated Long-Term Clinical Results from a Tab-cel® Multicenter Expanded Access Protocol EAP Study for Patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease EBV+ PTLD at the 61st American Soci

2019-11-26 16:00:10 | Atara Biotherapeutics to Participate at Evercore ISI Second Annual HealthCONx Conference

2019-11-12 09:00:02 | Atara Biotherapeutics ATRA Upgraded to Buy: Here's Why

2019-11-08 05:02:05 | Edited Transcript of ATRA earnings conference call or presentation 7-Nov-19 1:00pm GMT

2019-11-07 07:30:00 | Atara Biotherapeutics Announces Third Quarter 2019 Financial Results and Recent Clinical, Operational and Strategic Progress

2019-11-06 09:01:00 | Atara Biotherapeutics to Present Tab-cel® Long-Term Clinical Outcomes from a Multicenter Expanded Access Protocol EAP Study for Patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease EBV+ PTLD at the 61st American Society

2019-10-30 16:05:05 | Atara Biotherapeutics to Announce Third Quarter 2019 Operational Progress and Financial Results on Thursday, November 7, 2019

2019-10-28 12:39:07 | Did Hedge Funds Drop The Ball On Atara Biotherapeutics Inc ATRA?

2019-10-25 18:11:13 | Atara Biotherapeutics Announces Executive Departures

2019-09-27 11:54:14 | ATRA Stock Hits Five-Year Low on Goldman Bear Note

2019-09-27 10:50:00 | Atara Biotherapeutics Stock Falls After Goldman Downgrade

2019-09-26 07:37:21 | Is Atara Biotherapeutics NASDAQ:ATRA In A Good Position To Invest In Growth?

2019-09-23 13:16:18 | Seth Klarman Further Increases Translate Bio Stake

2019-09-23 05:54:09 | 3 Biotech Stocks Surging on Positive Results